1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 27 JULY 2015

Cancer Drug News 27 JULY 2015

  • July 2015
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - Oncology Will Be Driving Force Of BMS' Revenues
Industry Brief - CASI Pharmaceuticals Launches Zevalin For NHL
Industry Brief - FDA Approval Sought For Arzerra As Maintenance Therapy For Relapsed CLL
Industry Brief - EMA Validates Empliciti MAA For MM
Industry Trend Analysis - Looming Competition Overshadows Kyprolis' Expanded Indication
Industry Brief - EC Approves Nivolumab BMS For Previously-Treated Advanced Squamous NSCLC
Industry Brief - Final NICE Guidance Recommends BI's Vargatef
Industry Brief - Ono Seeks NSCLC Approval For Opdivo In Japan
Industry Brief - Telesta/BL&H Sign South Korea MCNA Distribution Deal
Industry Trend Analysis - Opdivo Poised To Capitalise On Untapped RCC Market
Industry Brief - DSMB Recommends Continuation Of Enrolment In ERY-ASP Phase II PC Study
Industry Brief - AstraZeneca’s Selumetinib Phase III Study In Uveal Melanoma Misses Primary Endpoint
Industry Brief - Keytruda Gains EU Approval For Advanced Melanoma
Industry Brief - Tafinlar+Mekinist Gains CHMP Positive Opinion/FDA Priority Review For Advanced Melanoma
Industry Trend Analysis - US Biosimilar Market Tangible But Zarxio's Acceptance Will Be Challenging
Industry Trend Analysis - Resubmitted Sustol Will Be Growth Driver In CINV Drugs Market
Industry Brief - EMA Validates Two Parallel Type II Variation Applications To Extend Opdivo Indication
Industry Brief - Baxalta Completes Oncaspar Portfolio Acquisition From Sigma-Tau

Table Of Contents

Cancer Drug News 27 JULY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.